Enbrel (We are no longer accepting cases on this product)
Enbrel was approved by the U.S. Food and Drug Administration on November 2, 1998, as the first of a new class of drugs for rheumatoid arthritis known as biologic response modifiers. On May 28, 1999, it was approved for the treatment of some cases of juvenile rheumatoid arthritis. It has been used by more than 80,000 patients in the United States to treat these disorders. Adult patients inject it themselves. Enbrel is co-marketed by Immunex and Wyeth-Ayerst Pharmaceuticals. Patients being given Enbrel have experienced several side effects, particularly:
- susceptibility to infection
- sepsis and other serious blood disorders
- serious nervous system disorders such as multiple sclerosis, seizures, and inflammation of the nerves of the eyes.
Physicians treating patients with Enbrel had reported “rare cases of central nervous system disorders, including demyelinating disorders such as multiple sclerosis, myelitis, and optic neuritis,” as well as “rare cases of pancytopenia, including aplastic anemia, some with a fatal outcome.”